Genfit (GNFT.PA) Stock Price
Genfit Price
Over the last 19 years Genfit grew revenue by 10.4% annually, reaching 65.43 M EUR. Earnings per share have grown at 0.4% per year over the last 18 years. For Genfit, the net margin of -131.4% is down versus 84.0% a few years ago. The consensus 12-month price target for Genfit is 9.18 EUR, about 0.9% above where the stock trades today. Of 12 analysts, 11 rate the stock a buy — an overall Buy consensus.
Genfit stock price
Genfit business model & stock analysis
Frequently asked questions about Genfit
Genfit SA's business model focuses on developing and commercializing innovative therapeutic solutions for patients with metabolic and liver-related diseases. The company primarily specializes in non-alcoholic steatohepatitis (NASH), which is a progressive disease of the liver. Genfit SA's business strategy involves conducting research and development activities, clinical trials, and obtaining regulatory approvals. By creating a pipeline of potential drug candidates, Genfit SA aims to address the unmet medical needs of individuals suffering from NASH and related conditions. The company's ultimate goal is to provide effective treatment options and improve the overall quality of life for patients in this specific market.
Genfit SA is primarily active in the pharmaceutical and biotechnology industries.
The main competitors of Genfit SA in the market are Intercept Pharmaceuticals, Inc., Viking Therapeutics, Inc., and Madrigal Pharmaceuticals, Inc.
Genfit SA is a renowned biopharmaceutical company based in France. Established in 1999, Genfit specializes in the development of innovative therapeutic and diagnostic solutions to address metabolic, inflammatory, and liver diseases. With a strong focus on pioneering research and advanced clinical trials, Genfit has positioned itself as a leading player in the pharmaceutical industry. The company's primary mission is to improve patient outcomes by combating diseases that represent significant medical and social challenges. Genfit SA continually strives to create value for its stakeholders through its commitment to scientific excellence, strategic collaborations, and dedication to addressing unmet medical needs.
Genfit SA, a leading biopharmaceutical company, has achieved numerous significant milestones. Notably, the company successfully completed Phase 3 clinical trials for its investigational drug, elafibranor, in patients with nonalcoholic steatohepatitis (NASH). This milestone is remarkable as it demonstrated the drug's potential in treating a widespread liver disease with no approved therapies. Genfit SA also received Breakthrough Therapy designation from the FDA, highlighting the drug's promising efficacy and safety profile. Moreover, the company has established strong collaborations, such as the strategic alliance with LabCorp, to advance the diagnosis and treatment of NASH. Genfit SA continues to forge ahead in its mission to address significant unmet medical needs and improve patient outcomes.
Genfit SA is primarily present in various countries and regions. The company operates not only in its home country, France, but also has a significant presence in the United States. Genfit SA also has a growing presence in other parts of the world, including Europe and Asia. This global expansion allows the company to reach a wider market and tap into diverse patient populations. With its increasing footprint, Genfit SA is well-positioned to cater to the needs of patients and healthcare providers in different countries and regions, driving its growth and success.
Genfit SA represents several core values and a strong corporate philosophy. The company prioritizes innovation and strives to develop groundbreaking solutions in the field of liver and metabolic diseases. Genfit SA is committed to patient-centric research and aims to improve the lives of individuals suffering from these ailments. With a focus on scientific excellence and commitment to ethical practices, Genfit SA believes in fostering collaborations and partnerships to drive progress. By combining cutting-edge research and a patient-oriented approach, Genfit SA aims to become a leading global biopharmaceutical company in its targeted therapeutic areas.
Analysts currently set an average price target of 11.18 EUR for the Genfit stock (median: 9.18 EUR), implying +22.8 % versus the latest price. The consensus is based on 12 analyst ratings.
12 analysts currently rate the Genfit stock: 11 recommend buying, 1 holding and 0 selling. For 2026, analysts expect Genfit to generate revenue of 93.77 M EUR and earnings per share of -0.18 EUR.
The Genfit share (GNFT.PA) is listed on 7 stock exchanges, including: London (0QT6.L), Frankfurt (XUP.F), München (XUP.MU), Düsseldorf (XUP.DU), Paris (GNFT.PA).
Genfit SA is a French biotech company focused on the development and commercialization of therapies for the treatment of metabolic diseases. The company is listed on the Euronext stock exchange in Paris and also has a branch in the US. Genfit SA utilizes an integrated business model that focuses on three main activities: research and development, diagnostics, and therapeutics.
The expected revenue of Genfit is 93.77 M EUR. This figure is based on current financial data and reflects the company's business performance.
The expected profit of Genfit is -9.07 M EUR. The net profit reflects the company's profitability after deducting all expenses.
The price-to-earnings ratio (P/E) of Genfit is currently -50.02. The P/E ratio compares the current share price to the earnings per share and helps investors assess the valuation of the Genfit stock.
The price-to-sales ratio (P/S) of Genfit is currently 4.84. The P/S ratio compares the market capitalization to the annual revenue and serves as a valuation metric for the Genfit stock.
The Eulerpool Quality Score for Genfit is 3/10.
The ISIN of Genfit is FR0004163111. The ISIN (International Securities Identification Number) is a globally unique identifier for securities.
The WKN of Genfit is A0LGJ2. The WKN (Wertpapierkennnummer) is a six-digit German security identification number.
The ticker of Genfit is GNFT.PA. The ticker symbol is used to trade Genfit shares on the stock exchange.
Genfit stock
Genfit Ticker
Genfit FIGI
All fundamentals and in-depth analysis of Genfit
Our stock analysis for Genfit stock includes important financial indicators such as revenue, profit, P/E ratio, P/S ratio, EBIT, as well as information on dividends. We also assess aspects such as stocks, market capitalization, debt, equity, and liabilities of Genfit. If you are looking for more detailed information on these topics, we offer comprehensive analyses on our subpages.